Ethnicity and antidepressant response

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 320-325

  Sramek, John J ^a   Edmond, H ^b  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DESIPRAMINE; NORTRIPTYLINE;

DRUG METABOLISM; ETHNOLOGY; HUMAN; PHARMACODYNAMICS; RACE DIFFERENCE; REVIEW;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CONTINENTAL POPULATION GROUPS; CROSS-CULTURAL COMPARISON; ETHNIC GROUPS; HUMANS;

EID: 16044367178     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Dawkins K, Manji HK, Potter WZ. Pharmacodynamics of antidepressants. In: Cutler NR, Sramek JJ, Narang PK, editors. Pharmacodynamics and drug development: perspectives in clinical pharmacology. Chichester, England: John Wiley & Sons Ltd, 1994:157-180.
2. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity, and clinical prediction of tricyclic drug effects in depression. Psychiatry Med 1987; 17:297-309
3. Potter WZ, Rudorfer MV, Linnoila M. New clinical studies support a role of norepinephrine antidepreasant action. In: Barchas JD, Bunney Jr. WE, editors. Perspectives in psychopharmacology. New York: Alan R Liss; 1988: 495-513.
4. Bertilsson L, Mellstršm B, Nordin C, et al. In: Gram LF, Usdin E, Dahl SG, et al. editors. Clinical pharmacology in psychiatry: bridging the experimental-therapeutic gap. London: Macmillan Press, 1983:217-226.
5. Brisen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985; 57:357-360.
6. Meyer OA. Molecular genetics and the future of pharmacokinetics. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press; 1992.
7. Yamamoto J, Fung D, Lo S, Reece S. Psychopharmacology for Asian Americans and Pacific Islanders. Psychopharmacol Bull 1979; 15:29-31.
8. Yamashita I, Asano Y. Tricyclic antidepressants: therapeutic plasma level. Psychopharmacol Bull 1979; 15: 40-44.
9. Pi EH, Jain A, Simpson GM. Review and survey of different prescribing practice in Asia. In: Shagass C, Josiassen RC, Bridger W, Weiss KJ, editors. Biological psychiatry. New York: Elsevier Science Inc 1986:1536-1538.
10. Benet LZ. Foreward. In: Cutler NR, Sramek JJ, Narang PK, editors. Pharmacodynamics and drug development: perspectives in clinical pharmacology. Chichester, England: John Wiley & Sons Ltd; 1994: xiii-xv.
11. Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers: preliminary report on a pilot study. Postgrad Med J 1977; 53(S4):79-86.
12. Lewis P, Rack PH, Vaddadi KS, Allen JJ. Ethnic differences in drug response. Postgrad Med J 1980; 56(S1): 46-49.
13. Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokmetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17:433-440.
14. Rudorfer MV, Lane EA, Potter WZ. Interethnic dissociation between debrisoquine and desipramine hydroxylation. J Clin Psychopharmacol 1985; 5:89-92.
15. Kishimoto A, Hollister LE. Nortriptyline kinetics in Japanese and Americans. J Clin Psychopharmacol 1984; 4:171-172.
16. Pi EH, Simpson GM, Cooper TB. Pharmacokinetics of desipramine in Caucasian and Asian volunteers. Am J Psychiatry 1986; 143:1174-1176.
17. Pi EH, Tran-Johnsan TK, Walker NR, et al. Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol Bull 1989; 25:483-487.
18. Shimoda K, Noguchi T, Ozeki Y, et al. Metabolism of clomipramine in a Japanese psychiatric population: hydroxylation, desmethylation, and glucuronidation. Neuropsychopharmacology 1995; 12:323-333.
19. Ziegler VE, Briggs JT. Tricyclic plasma levels - effect of age, race, sex, and smoking. JAMA 1977; 438:2167-2169.
20. Strickland T, Lin KM, Fu P, et al. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol Psychiatry 1995; 37:325-330.
21. Gaviria M, Gil AA, Javaid JI. Nortriptyline kinetics in Hispanic and Anglo subjects. J Clin Psychopharmacol 1986; 6:227-231.
22. Glassman AH, Perel JM, Shostak M, et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34:197-204.
23. Yang YY. Prophylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatr Scand 1985; 71:171-175.
24. Chang SS, Pandey GN, Zhang MY, et al. Racial differences in plasma and RBC lithium levels. Presented at the Annual Meeting of the American Psychiatric Association, May 5-11, Los Angeles, CA. Continuing Medical Education Syllabus and Scientific Proceedings 1984:239-240.
25. Chang SS, Pandey GN, Yang YY, et al. Lithium pharmacokinteics: interracial comparison. Presented at the 138th Annual Meeting of the American Psychiatric Association; 1985 May 19-24; Dallas, Texas.
26. Jefferson JW, Greist JH, Ackerman DL, Carrol JA, editors. Lithium encyclopedia for clinical practice. 2nd ed. Washington DC: American Psychiatric Press; 1987.
27. Raskin A, Crook TH. Antidepressants in black and white inpatients. Arch Gen Psychiatry 1975; 32:643-649.
28. Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry 1983; 44:173-176.
29. Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects of tricyclic antidepressant plasma levels. J Clin Psychiatry 1982; 42:457-460.
30. Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychotherapy 1982; 36:505-513.
31. Pi EH, Wang AL, Gray GE. Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: a review. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:691-702.
32. Escobar JI. Are results on the dexamethasone suppression test affected by ethnic background? (letter). Am J Psychiatry 1985; 142:268.
33. de la Fuente JR, Sepulveda Amor J. Does ethnicity affect DST results? (letter). Am J Psychiatry 1986; 143:275-276.
34. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinease and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-397.
35. Nakamura K, Goto R, Ray WA, et al. Interethnic differences in generic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
36. Horai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese vs. mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.